Adma Biologics 

$13.85
239
+$0.17+1.24% 13:54 Today

Statistics

Day High
13.69
Day Low
13.66
52W High
20.46
52W Low
7.21
Volume
129,371
Avg. Volume
-
Mkt Cap
3.03B
P/E Ratio
13.35
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
0.14
0.17
0.2
0.23
Expected EPS
0.196667
Actual EPS
0.225216

Financials

28.8%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
510.17MRevenue
146.93MNet Income

Analyst Ratings

$15.00Average Price Target
The highest estimate is ⁦17.00⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADMA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap68.47B
Takeda Pharmaceutical Company, through its plasma-derived therapies and subunit vaccines, competes in similar therapeutic areas as ADMA.
Carlisle Companies
CSL
Mkt Cap15.31B
CSL Behring operates in the plasma protein biotherapeutics area, directly competing with ADMA's immune globulin products.
Grifols SA
GRFS
Mkt Cap5.91B
Grifols, S.A. specializes in plasma-derived biopharmaceuticals, offering products that overlap with ADMA's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.09B
BioMarin Pharmaceutical focuses on rare diseases treated by genetic and plasma-derived therapies, competing in the same niche as ADMA.
Pfizer
PFE
Mkt Cap164.67B
Pfizer has a broad portfolio that includes immunoglobulin therapies, competing with ADMA in the immune globulin market.
GSK
GSK
Mkt Cap101.13B
GlaxoSmithKline produces vaccines and plasma-derived medicinal products, making it a competitor in ADMA's market space.
Abbvie
ABBV
Mkt Cap521.5B
AbbVie, with its biopharmaceutical products, competes in the immunology and plasma-derived therapeutic areas relevant to ADMA.
AMGEN
AMGN
Mkt Cap251.89B
Amgen's focus on innovative therapeutics and biologics in areas like immunology poses competition to ADMA's product offerings.
Biogen
BIIB
Mkt Cap37.46B
Biogen's portfolio includes therapies for neurological and autoimmune diseases, competing with ADMA in the specialty biologics space.
Johnson & Johnson
JNJ
Mkt Cap687.89B
Johnson & Johnson, through its pharmaceutical segment, offers products that compete with ADMA's immunoglobulin and plasma-based therapies.

About

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Show More
CEO
Adam S. Grossman
Employees
647
Country
United States
ISIN
US0008991046

Listings

0 Comments

Share your thoughts

FAQs

What is Adma Biologics stock price today?▼
The current price of ADMA is $13.85 USD — it has increased by +1.24% in the past 24 hours. Watch Adma Biologics stock price performance more closely on the chart.
What is Adma Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adma Biologics stocks are traded under the ticker ADMA.
Is Adma Biologics stock price growing?▼
ADMA stock has risen by +6.96% compared to the previous week, the month change is a +28.09% rise, over the last year Adma Biologics has showed a -12.08% decrease.
What is Adma Biologics market cap?▼
Today Adma Biologics has the market capitalization of 3.03B
When is the next Adma Biologics earnings date?▼
Adma Biologics is going to release the next earnings report on March 25, 2027.
What were Adma Biologics earnings last quarter?▼
ADMA earnings for the last quarter are 0.23 USD per share, whereas the estimation was 0.2 USD resulting in a +14.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adma Biologics revenue for the last year?▼
Adma Biologics revenue for the last year amounts to 510.17M USD.
What is Adma Biologics net income for the last year?▼
ADMA net income for the last year is 146.93M USD.
How many employees does Adma Biologics have?▼
As of November 16, 2026, the company has 647 employees.
In which sector is Adma Biologics located?▼
Adma Biologics operates in the Health & Wellness sector.
When did Adma Biologics complete a stock split?▼
Adma Biologics has not had any recent stock splits.
Where is Adma Biologics headquartered?▼
Adma Biologics is headquartered in RAMSEY, United States.